AN2 Therapeutics, Inc.
ANTX
$-0.07
Change (1 day)
$22.22
Year High
$0.87
Year Low
Categories
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Earnings for AN2 Therapeutics, Inc. (ANTX)
Earnings in 2023 (TTM): $-64,732,000
According to AN2 Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-64,732,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of AN2 Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-64,732,000 | $-64,732,000 |
| 2022 | $-40,956,000 | $-41,470,000 |
| 2021 | $-21,543,000 | $-21,474,000 |
| 2020 | $-13,603,000 | $-13,600,000 |
| 2019 | $-5,635,000 | $-5,635,000 |